Quality of Life Depression Scale
The quality of life depression scale was developed in 1992. The QLDS assesses the impacts of depression on quality of life of a person. QLDS is a widely used scale for measuring the quality of life in studies of depression and clinical trials (Woldetensay et al., 2018). The QLDS presupposes that the quality of life of a person can be evaluated subjectively. The scale has been validated for use in many languages. QLDS is sensitive to changes in quality of life because it adopts the needs model.
Psychometric properties refer to reliability and the validity of a measurement tool. The quality of life depression scale has a 34 self-rated questionnaire. The questionnaire has dichotomous response questions, which are either true or not true (Christensen et al., 2020). The scores are generated binomially, ranging from 0-10. The highest score of the QLDS is an indication of the low quality of life. Various tests for internal and construct validity approved that QLDS is a good scale for measuring the quality of life. When QLDS used in clinical trials should have both test and retest reliability coefficient of 0.85 as the minimum. The internal consistency of clients with depression should be measured using Cronbach’s alpha coefficient with a minimum (Woldetensay et al., 2018).
It is appropriate to use quality of life depression scale because it represents a significant in our ability to comprehend how depression impacts the quality of life. Feelings of the people influence the use of health services than the portrayed objective symptoms. Moreover, compliance with the employment regime is dependent on impacts shown on the patient’s wellbeing (Christensen et al., 2020). The QLDS helps meet these patients’ needs by assessing the needs of a patient’s progress throughout their health care system by assessing the impact of the disease on the patient’s quality of life.
Psychopharmacological medications are medicines used for stabilizing mood, managing behaviors, or treating patients with psychiatric disorders. Some of the Psychopharmacological medications used are sedative-hypnotics, antipsychotics, antidepressants, and anxiolytics. The validated clinical rating scales for depression are used to determine the effect and size of each treatment administered to a patient. For this reason, I believe that the quality of life depression scale can be used to assess psychopharmacologic medications (Vasiliu et al., 2017). The scale ranges from 0-1. After measuring clients with depression, the results imply that patients who record low scores out of possibly 34 points indicate the high quality of life and vice versa. After the use of psychopharmacological medication, the QLDS test efficiency by determining whether the client score is declining from low to a high quality of life. For instance, after a patient takes medication, QLDS measures scores recorded by a client at different intervals; thus, score differences indicate the efficiency of psycho-pharmacological medications.
Christensen,A.V., Dixon,J.K., Juel,K., Ekholm,O., Rasmussen,T.B., Borregaard,B., Mols,R.E., Thrysøe,L., Thorup,C.B., & Berg,S.K. (2020). Psychometric properties of the Danish hospital anxiety and depression scale in patients with cardiac disease: Results from the DenHeart survey.Health and Quality of Life Outcomes,18(1).https://doi.org/10.1186/s12955-019-1264-0
Vasiliu, O., Vasile, D., Vasiliu, D., Andreea Filareta, A., & Vasile, F. (2017). Quetiapine XR as an add-on to antidepressants in treatment-resistant late-life major depression. European Psychiatry,41(S1), S144-S144.https://doi.org/10.1016/j.eurpsy.2017.01.1985
Woldetensay,Y.K., Belachew,T., Tesfaye,M., Spielman,K., Biesalski,H.K., Kantelhardt,E.J., & Scherbaum,V. (2018). Validation of the patient health questionnaire (PHQ-9) as a screening tool for depression in pregnant women: Afaan Oromo version.PLOS ONE,13(2), e0191782.https://doi.org/10.1371/journal.pone.0191782